Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics reported a net loss of $(5.82) million for the six months ended June 30, 2026, an improvement from $(7.51) million in the prior year period. Despite the reduced loss, the company's cash and cash equivalents declined to $2.39 million, leading management to express "substantial doubt" about its ability to continue as a going concern. The company also highlighted recent asset acquisitions for its pipeline, including frunexian and CAD-1005, and capital raised through warrant inducements and ATM sales.

Cadrenal Therapeutics reported its second quarter 2026 financial results, including a net loss of $3.3 million and $4.2 million in cash and cash equivalents, expected to fund operations through Q1 2027. Concurrently, the company launched a strategic partnering process for its pipeline assets, CAD-1005, frunexian, and tecarfarin, following positive Phase 2 data for CAD-1005 and a regulatory submission for tecarfarin. The company aims for a capital-efficient model through out-licensing and portfolio monetization.

Cadrenal Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 24, 2026. Stockholders will vote on several key proposals, including the election of a Class I director, the ratification of its independent auditor, and significant equity-related matters. These include an amendment to increase the 2022 Equity Incentive Plan shares by 323,542 to a total of 1,000,000, and the approval for the issuance of up to 960,000 shares upon the exercise of Series C-1 warrants from a recent private placement.

Cadrenal Therapeutics is consolidating its multi-indication strategy for CAD-1005, focusing on both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This intensified focus on CSA-AKI follows a competitor's recent Phase 3 failure, opening a $1 billion+ market opportunity for CAD-1005. The company highlighted compelling Phase 2 data for CAD-1005, showing over 25% reduction in thrombotic events and a renal-protective baseline. Cadrenal is actively seeking strategic partnerships for its Phase 3-ready asset.

Cadrenal Therapeutics announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. The company has initiated a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets, including CAD-1005, frunexian, and tecarfarin. This strategy aims to maximize asset value and accelerate commercialization, supported by recent positive Phase 2 data for CAD-1005 showing a significant reduction in thrombotic events. Additionally, Cadrenal is advancing its preclinical oral 12-LOX inhibitor, CAD-2000, and expanding tecarfarin's clinical protocols for rare pediatric diseases like Kawasaki Disease.

Cadrenal Therapeutics announced late-breaking Phase 2 clinical data for its lead candidate, CAD-1005, presented at the ISTH 2026 Congress. The data highlighted CAD-1005 as the first randomized, blinded, placebo-controlled trial for Heparin-Induced Thrombocytopenia (HIT), showing an absolute reduction of over 25% in thrombotic events. This supports the clinical advancement of the Phase 3-ready program, which targets a life-threatening condition with an estimated $2 billion in peak annual revenue and no approved root-cause therapies.

Cadrenal Therapeutics, Inc. announced that its Chief Medical Officer, James J. Ferguson III, advised the Board of Directors of his decision to resign. His resignation is effective July 31, 2026. The company has initiated a search for his replacement and is negotiating the terms of separation with Dr. Ferguson.

Cadrenal Therapeutics, Inc. announced a definitive agreement for a private placement with a single healthcare-focused institutional investor, raising $3 million in gross proceeds. The offering includes common stock (or pre-funded warrants) and Series C-1 and C-2 warrants, with potential additional gross proceeds of approximately $5.8 million if all warrants are fully exercised. The net proceeds are expected to extend the company's cash runway into the first quarter of 2027, or into the second half of 2027 if warrants are fully exercised, to advance partnering opportunities for tecarfarin and CAD-1005.

Cadrenal Therapeutics, Inc. announced the appointment of John P. Sharp as Interim Chief Financial Officer, effective June 25, 2026, replacing Quang X. Pham. Mr. Sharp's services will be provided via Lohman & Associates at a rate of $455 per hour for up to 24 hours weekly. Additionally, Steven Zelenkofske resigned from the Board of Directors, effective June 30, 2026, leading to a re-alignment of Board classes and the re-appointment of Dr. Glynn Wilson as a Class III director and to several committees.

Cadrenal Therapeutics, Inc. announced its plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin. This designation targets pediatric patients with Kawasaki disease who develop coronary artery aneurysms and require chronic oral anticoagulation. If granted and subsequently approved, the company would be eligible for a Priority Review Voucher, which has recently been valued between $180 million and $205 million. Additionally, Cadrenal outlined a dual-track portfolio strategy, focusing on CAD-1005 for global pharmaceutical opportunities and tecarfarin for regional and rare disease markets.